Cefepime and Ceftazidime Safety in Hospitalized Infants

Clinical Pharmacology of Cefepime in Infants and Children

Cefepime is a fourth-generation cephalosporin which is approved in Europe and in the USA. Food and Drug Administration (FDA) approves cefepime in the treatment of febrile neutropenia. Cefepime is active against gram-negative microorganisms such as Escherichia coli, Haemophilus influenzae, Enterobacter, Klebsiella, Morganella, Neisseria, Serratia, and Proteus species. Cefepime is also active aga...

Safety of octreotide in hospitalized infants.

BACKGROUND Octreotide is used off-label in infants for treatment of chylothorax, congenital hyperinsulinism, and gastrointestinal bleeding. The safety profile of octreotide in hospitalized infants has not been described; we sought to fill this information gap. METHODS We identified all infants exposed to at least 1 dose of octreotide from a cohort of 887,855 infants discharged from 333 neonat...

Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects.

We undertook a prospective, randomized open comparison of the broad-spectrum cephalosporins cefepime and ceftazidime in treatment of hospitalized subjects with skin or wound infections and complicated nosocomial urinary tract infections. Cefepime treatment (dosage, 2.0 g intravenously twice daily for 4 to 28 days) was successful in 36 (90%) of 40 infections of the skin and skin structure or wou...

Ceftazidime to cefepime formulary switch: pharmacodynamic and pharmacoeconomic rationale.

Pharmacokinetics of ceftazidime in newborn infants.

Doses of 50 mg of ceftazidime per kg were administered intravenously to 29 newborn infants every 8 or 12 h for 3 to 5 days. Mean peak concentrations in plasma ranged from 102 to 124 micrograms/ml. Mean elimination half-life values ranged from 2.9 to 6.7 h and varied inversely with gestational age and plasma clearances. Peak and trough plasma bactericidal titers against an Escherichia coli and a...